文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

预防性抗生素对重度酒精相关性肝炎死亡率的影响:一项随机临床试验

Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

该多中心随机双盲试验纳入活检证实的重度酒精相关性肝炎患者292例,比较泼尼松龙联合阿莫西林-克拉维酸与联合安慰剂对60天全因死亡率的影响。结果显示两组60天死亡率无显著差异,联合阿莫西林-克拉维酸组60天感染率显著低于安慰剂组。结论不支持预防性使用抗生素以改善生存。

要点

  • 泼尼松龙联合阿莫西林-克拉维酸与联合安慰剂相比,60天全因死亡率无显著差异。
  • 阿莫西林-克拉维酸组60天感染率显著低于安慰剂组。
  • 结果不支持对住院重度酒精相关性肝炎患者预防性使用抗生素以改善生存。

核心结论

  • 在住院的重度酒精相关性肝炎患者中,与单用泼尼松龙相比,阿莫西林-克拉维酸联合泼尼松龙未改善2个月生存。
  • 这些结果不支持预防性使用抗生素以改善住院重度酒精相关性肝炎患者的生存。

研究设计与样本

  • 多中心、随机、双盲临床试验,2015年6月13日至2019年5月24日在法国和比利时的25个中心进行。
  • 纳入经活检证实的重度酒精相关性肝炎患者(Maddrey功能评分≥32且终末期肝病模型[MELD]评分≥21),所有患者随访180天,最终随访于2019年11月19日。
  • 患者按1:1随机分配至泼尼松龙联合阿莫西林-克拉维酸组(n=145)或泼尼松龙联合安慰剂组(n=147);292例随机患者中284例(97%)纳入分析。

主要发现

  • 60天全因死亡率:阿莫西林-克拉维酸组17.3% vs 安慰剂组21.3%(P=.33),组间差异-4.7%(95%CI,-14.0%至4.7%),风险比0.77(95%CI,0.45-1.31),无显著差异。
  • 60天感染率:阿莫西林-克拉维酸组29.7% vs 安慰剂组41.5%,平均差异-11.8%(95%CI,-23.0%至-0.7%),亚风险比0.62(95%CI,0.41-0.91),P=.02,阿莫西林-克拉维酸组显著更低。
  • 其余3项次要结局均无显著差异。
  • 最常见的严重不良事件涉及肝衰竭(阿莫西林-克拉维酸组25例 vs 安慰剂组20例)、感染(阿莫西林-克拉维酸组23例 vs 安慰剂组46例)和胃肠道疾病(阿莫西林-克拉维酸组15例 vs 安慰剂组21例)。

关键数值与推荐

  • 主要结局为60天全因死亡率。
  • 次要结局包括90天和180天全因死亡率、感染发生率、肝肾综合征发生率、60天时MELD评分低于17分的参与者比例、7天时Lille评分低于0.45分的患者比例。

临床怎么用

  • 原文结论认为这些结果不支持预防性使用抗生素以改善住院重度酒精相关性肝炎患者的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The benefits of prophylactic antibiotics for hospitalized patients with severe alcohol-related hepatitis are unclear. OBJECTIVE: To determine the efficacy of amoxicillin-clavulanate, compared with placebo, on mortality in patients hospitalized with severe alcohol-related hepatitis and treated with prednisolone. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind clinical trial among patients with biopsy-proven severe alcohol-related hepatitis (Maddrey function score ≥32 and Model for End-stage Liver Disease [MELD] score ≥21) from June 13, 2015, to May 24, 2019, in 25 centers in France and Belgium. All patients were followed up for 180 days. Final follow-up occurred on November 19, 2019. INTERVENTION: Patients were randomly assigned (1:1 allocation) to receive prednisolone combined with amoxicillin-clavulanate (n = 145) or prednisolone combined with placebo (n = 147). MAIN OUTCOME AND MEASURES: The primary outcome was all-cause mortality at 60 days. Secondary outcomes were all-cause mortality at 90 and 180 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants with a MELD score less than 17 at 60 days; and proportion of patients with a Lille score less than 0.45 at 7 days. RESULTS: Among 292 randomized patients (mean age, 52.8 [SD, 9.2] years; 80 [27.4%] women) 284 (97%) were analyzed. There was no significant difference in 60-day mortality between participants randomized to amoxicillin-clavulanate and those randomized to placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [P = .33]; between-group difference, -4.7% [95% CI, -14.0% to 4.7%]; hazard ratio, 0.77 [95% CI, 0.45-1.31]). Infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, -11.8% [95% CI, -23.0% to -0.7%]; subhazard ratio, 0.62; [95% CI, 0.41-0.91]; P = .02). There were no significant differences in any of the remaining 3 secondary outcomes. The most common serious adverse events were related to liver failure (25 in the amoxicillin-clavulanate group and 20 in the placebo group), infections (23 in the amoxicillin-clavulanate group and 46 in the placebo group), and gastrointestinal disorders (15 in the amoxicillin-clavulanate group and 21 in the placebo group). CONCLUSION AND RELEVANCE: In patients hospitalized with severe alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone did not improve 2-month survival compared with prednisolone alone. These results do not support prophylactic antibiotics to improve survival in patients hospitalized with severe alcohol-related hepatitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02281929.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Louvet A, Labreuche J, Dao T, et al. Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial. JAMA. 2023. PMID: 37159035. doi:10.1001/jama.2023.4902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。